Fibrotic Disease

Fibrotic Diseases encompass a group of disorders characterized by the abnormal accumulation of fibrous connective tissue, primarily collagen, in organs and tissues throughout the body. This excessive fibrosis disrupts normal tissue architecture, impairing organ function and leading to significant health complications. Conditions such as pulmonary fibrosis, liver cirrhosis, and systemic sclerosis exemplify fibrotic diseases, each affecting distinct organ systems. Fibrotic processes typically result from chronic inflammation, tissue injury, or unresolved wound healing, prompting the activation of fibroblasts and their transformation into myofibroblasts. These cells play a central role in producing excessive amounts of collagen and other extracellular matrix components, leading to scar formation and tissue stiffening. The relentless progression of fibrosis can compromise organ function, contributing to respiratory insufficiency, liver dysfunction, and other organ-specific manifestations. Genetic predisposition, environmental factors, and autoimmune responses are among the diverse triggers implicated in fibrotic diseases. Current therapeutic strategies focus on alleviating symptoms and slowing disease progression, but effective treatments targeting the underlying fibrotic mechanisms remain a significant challenge. Ongoing research aims to unravel the complex molecular pathways involved in fibrosis, offering hope for the development of targeted therapies to mitigate the impact of these debilitating conditions on global health.